Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Amicus Makes Steady Progress Toward Achievement of Milestones

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.36 per share ($0.29 per share on a non-GAAP basis) for the three months ended September 30, 2008. As of September 30, 2008, cash, cash equivalents, and marketable securities totaled $136.3 million.

"The third quarter of 2008 was another quarter of strong progress for Amicus as we focused on clinical and regulatory execution on our three lysosomal storage disease programs," said John F. Crowley, President and CEO of Amicus Therapeutics. "In recent months, we have continued the process with regulatory authorities in the United States and Europe in order to define the global development plan for Amigal(TM) in Fabry, and we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease programs, we continue to focus on advancing our ongoing Phase 2 clinical trials with the goal of reporting data in Gaucher in 2009. Finally, our financial position remains strong based on a healthy balance sheet and on the economics from our strategic alliance with Shire, which funds 50% of development costs for our lead programs in addition to success-based clinical and regulatory milestone payments."

Program Advancements

Fabry Disease:

Amigal (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Amicus, along with its partner Shire Human Genetic Ther
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Seoul Semiconductor (CEO: Chung-hoon ... technology, on May 28th announced that it will ... strengthening its high efficient and high reliable LED ... 2011 Seoul Semiconductor has developed efficient and reliable ... has supplied LEDs for headlamps to global auto ...
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... IN (PRWEB) May 28, 2015 The Academy ... National Model Aviation Day on August 15, 2015. National Model ... aviation nation-wide and to introduce model flying to the general ... 2,350 chartered clubs to participate in the celebration by hosting ... registered to host National Model Aviation Day events. View ...
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology ... cancer immunotherapy treatment targeting HPV-16, has generated strong ... Currently, pre-cervical cancer is treated by surgical ... simple and effective non-surgical alternative. Results show that ... (T-cells) to recognize, target, and kill precancerous and ...
Breaking Biology Technology:Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... BOTHELL, WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - OncoGenex ... it has entered into purchase agreements with certain institutional ... common stock at a price of $20 per share ... to provide gross proceeds of $9.5 million to OncoGenex ...
... , , ST. LOUIS, July 20 ... first outpatient single-site laparoscopic gastric banding surgery in the state of Missouri ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/CLTU111LOGO ... For single-site surgery, the major incision is through the belly button only. ...
... , NEWPORT, R.I., July 20 iSource ... today that it will partner with inVentiv Health, the ... to develop an innovative new technology platform that will ... to better manage their health. The platform will be ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock 2OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock 3Surgeon Performs First Single Incision Peri-Umbilical Laparoscopic Surgery in the State of Missouri 2iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers 2iSource Networks Partners with inVentiv Health to Develop New Technology Platform for Reaching Healthcare Consumers 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... of scientists has released data indicating that greenhouse gas ... of methane emissions from freshwater areas. John Downing, ... and organismal biology department, is part of an international ... is higher than previous estimates. The study, ...
... a significant step forward in understanding the atmosphere,s ... some other gases, except carbon dioxide. The issue ... studies suggesting the self-cleaning power of the atmosphere ... others suggest greater stability. And what researchers are ...
... 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical company ... and tissues including muscle, bone, fat, red blood cells ... a $1.5 million grant from the Muscular Dystrophy Association ... Dystrophy (DMD), a disabling neuromuscular disease in which patients ...
Cached Biology News:Freshwater methane release changes greenhouse gas equation 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031 2